Morand O - Search Results

1

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.

Guérard N, Morand O, Dingemanse J. Guérard N, et al. Among authors: morand o. Orphanet J Rare Dis. 2017 Jan 14;12(1):9. doi: 10.1186/s13023-017-0565-9. Orphanet J Rare Dis. 2017. PMID: 28088251 Free PMC article. Clinical Trial.

2

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.

Guérard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford RWD, Dingemanse J, Wanner C. Guérard N, et al. Among authors: morand o. Clin Pharmacol Ther. 2018 Apr;103(4):703-711. doi: 10.1002/cpt.790. Epub 2017 Aug 28. Clin Pharmacol Ther. 2018. PMID: 28699267 Clinical Trial.

3

A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.

Remenova T, Morand O, Amato D, Chadha-Boreham H, Tsurutani S, Marquardt T. Remenova T, et al. Among authors: morand o. Orphanet J Rare Dis. 2015 Jun 19;10:81. doi: 10.1186/s13023-015-0297-7. Orphanet J Rare Dis. 2015. PMID: 26084276 Free PMC article. Clinical Trial.

4

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.

Welford RWD, Mühlemann A, Garzotti M, Rickert V, Groenen PMA, Morand O, Üçeyler N, Probst MR. Welford RWD, et al. Among authors: morand o. Hum Mol Genet. 2018 Oct 1;27(19):3392-3403. doi: 10.1093/hmg/ddy248. Hum Mol Genet. 2018. PMID: 29982630 Free PMC article.

5

The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.

Treiber A, Morand O, Clozel M. Treiber A, et al. Among authors: morand o. Xenobiotica. 2007 Mar;37(3):298-314. doi: 10.1080/00498250601094543. Xenobiotica. 2007. PMID: 17624027

6

Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.

Patterson MC, Garver WS, Giugliani R, Imrie J, Jahnova H, Meaney FJ, Nadjar Y, Vanier MT, Moneuse P, Morand O, Rosenberg D, Schwierin B, Héron B. Patterson MC, et al. Among authors: morand o. J Inherit Metab Dis. 2020 Sep;43(5):1060-1069. doi: 10.1002/jimd.12245. Epub 2020 May 8. J Inherit Metab Dis. 2020. PMID: 32324281 Free PMC article.

7

Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study.

Welford RW, Garzotti M, Marques Lourenço C, Mengel E, Marquardt T, Reunert J, Amraoui Y, Kolb SA, Morand O, Groenen P. Welford RW, et al. Among authors: morand o. PLoS One. 2014 Dec 5;9(12):e114669. doi: 10.1371/journal.pone.0114669. eCollection 2014. PLoS One. 2014. PMID: 25479233 Free PMC article.

8

Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey.

Morand O, Johnson J, Walter J, Atkinson L, Kline G, Frey A, Politei J, Schiffmann R. Morand O, et al. Adv Ther. 2019 Oct;36(10):2866-2880. doi: 10.1007/s12325-019-01061-x. Epub 2019 Aug 21. Adv Ther. 2019. PMID: 31435831 Free PMC article.

9

Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.

Cherradi S, Garambois V, Marines J, Andrade AF, Fauvre A, Morand O, Fargal M, Mancouri F, Ayrolles-Torro A, Vezzo-Vié N, Jarlier M, Loussaint G, Huvelle S, Joubert N, Mazard T, Gongora C, Pourquier P, Boissière-Michot F, Rio MD. Cherradi S, et al. Among authors: morand o. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5. Cell Biosci. 2023. PMID: 37041570 Free PMC article.

10

The Integration of Live Video Tools to Help Bystanders During an Emergency Call: Protocol for a Mixed Methods Simulation Study.

Morand O, Larribau R, Safin S, Pages R, Soichet H, Rizza C. Morand O, et al. JMIR Res Protoc. 2023 Feb 1;12:e40699. doi: 10.2196/40699. JMIR Res Protoc. 2023. PMID: 36723999 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page